MedTrace Logo

Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study

NCT05440357 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-02-26

No results posted yet for this study

Summary

This is a prospective, multicenter, observational real-world study to explore the second-line Pharmacotherapy patterns and clinical outcomes in GIST patients who progressed on or were intolerant to first-line anticancer treatment.

Conditions

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • Sixth Affiliated Hospital, Sun Yat-sen University

    collaborator OTHER

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • Cancer Hospital of Guangxi Medical University

    collaborator OTHER

  • Hainan Cancer Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Nanchang University

    collaborator OTHER

  • Second Affiliated Hospital of Nanchang University

    collaborator OTHER

  • Yunnan Cancer Hospital

    collaborator OTHER

  • Chongqing University Cancer Hospital

    collaborator OTHER

  • Xinhua Zhang, MD

    lead OTHER

Principal Investigators

  • zhang xinhua, PhD · First affiliated hosptial,Sun Yat-sen university

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05440357 on ClinicalTrials.gov